Botox (Allergan) approved by MHRA in UK for Urinary Incontinence
The Medicines and Healthcare products Regulatory Agency (MHRA)in the UK has given Botox (botulinum toxin type A) approval for managing Urinary Incontinence caused by neurogenic detrusor overactivity(NDO) due to subcervical spinal cord injury (SCI; traumatic or non-traumatic) or multiple sclerosis (MS), but only if treatment with anticholinergics does not work. Recently published NICE Guidelines recommend the use of botulinum toxin type A to treat patients with MS or SCI who have symptoms of an overactive bladder and in whom oral treatments have been ineffective or poorly tolerated.
Around 140,000 people in the UK are living with MS and SCI, of which between 75%-80% and 60%-80%, respectively, will suffer some degree of bladder dysfunction, including urinary leakage, caused by involuntary contractions of the bladder.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins